BioNTech SE (BNTX) Interest & Investment Income (2018 - 2026)
BioNTech SE (BNTX) posted Interest & Investment Income of $115.9 million for Q4 2025, up 2.45% sequentially from $113.2 million in Q3 2025, and down 34.32% YoY from $176.5 million in Q4 2024.
Analysis
BioNTech SE (BNTX) Interest & Investment Income (2018 - 2026) Analysis & Trends
BioNTech SE has reported Interest & Investment Income for 8 years, with the latest figure at $115.9 million in Q4 2025.
- Quarterly Interest & Investment Income fell 34.32% year-over-year to $115.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $477.4 million (down 34.09% YoY) and the FY2025 annual result came in at $478.9 million, down 32.5% from the prior year.
- Interest & Investment Income advanced to $115.9 million in Q4 2025 per BNTX's latest filing, from $113.2 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $305.4 million in Q1 2022 and troughed at $361281.4 in Q2 2021.
- A 5-year average of $120.5 million and a median of $121.3 million in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income soared 34013.31% in 2022, then plunged 71.07% in 2023.
- Over 5 years, Interest & Investment Income stood at $18.6 million in 2021, then soared by 112.29% to $39.6 million in 2022, then jumped by 340.86% to $174.5 million in 2023, then increased by 1.15% to $176.5 million in 2024, then sank by 34.32% to $115.9 million in 2025.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $115.9 million, $113.2 million, and $119.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 10.98 Mn |
| 10 | BioNTech SE | 25.17 Bn | 11.52 Bn | 10.00 Mn | 113.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 113.10 Mn |
| Mar 31, 2026 | 141.19 Mn |
| Dec 31, 2025 | 115.94 Mn |
| Sep 30, 2025 | 113.16 Mn |
| Jun 30, 2025 | 119.31 Mn |
| Mar 31, 2025 | 128.96 Mn |
| Dec 31, 2024 | 176.53 Mn |
| Sep 30, 2024 | 171.54 Mn |
| Jun 30, 2024 | 180.59 Mn |
| Mar 31, 2024 | 195.65 Mn |
| Dec 31, 2023 | 174.52 Mn |
| Sep 30, 2023 | 170.15 Mn |
| Jun 30, 2023 | 165.95 Mn |
| Mar 31, 2023 | 88.34 Mn |
| Dec 31, 2022 | 39.59 Mn |
| Sep 30, 2022 | 61.40 Mn |
| Jun 30, 2022 | 123.25 Mn |
| Mar 31, 2022 | 305.39 Mn |
| Dec 31, 2021 | 18.65 Mn |
| Sep 30, 2021 | 31.37 Mn |